|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 238.90 EUR | +1.31% |
|
+3.33% | +0.04% |
| 06:52am | H Lundbeck raises 2026 forecasts on US demand, delayed generic competition | RE |
| May. 07 | UCB: New partnership with Cancer Research UK and Cancer Research Horizons | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 52.9B | |||||
| 72.52B | |||||
| 45.93B | |||||
| 35.49B | - | ||||
| 29.22B | |||||
| 20.98B | - |
- Stock Market
- Equities
- UCB Stock
- Charts UCB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
